Aminotransferase levels and 20-year risk of metabolic syndrome, diabetes, and cardiovascular disease.

ABSTRACT:

Background & aims

Nonalcoholic fatty liver disease (NAFLD) is the hepatic manifestation of obesity and metabolic syndrome (MetS). Alanine aminotransferase (ALT) levels are used to detect NAFLD and have also been associated with increased risk for MetS, diabetes mellitus, and cardiovascular disease (CVD). We studied the relationship between ALT levels and these disorders in a long-term follow-up study.

Methods

Framingham Offspring Heart Study participants (n = 2812; mean age, 44 years; 56% women) were followed for the development of MetS, diabetes, CVD, and all-cause mortality using logistic regression (MetS, diabetes) or Cox proportional hazards models (CVD, all-cause mortality).

Results

Among individuals at baseline, per 1 standard deviation increase in log ALT level

SUBMITTER: Goessling W 

PROVIDER: S-EPMC3039001 | biostudies-literature | 2008 Dec

REPOSITORIES: biostudies-literature